Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988283 · ClinicalTrials.gov registry record · Phase 1
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors
A Phase 1 study of Pediatric Recurrent Central Nervous System Tumors, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03988283 is a Phase 1 study of Pediatric Recurrent Central Nervous System Tumors that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 7 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03988283, a Phase 1 study of Pediatric Recurrent Central Nervous System Tumors, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
Conditions Studied
Interventions
- PROCEDURE Peripheral blood draw
- BIOLOGICAL Personalized neoantigen DNA vaccine
- DEVICE Papivax Biotech TDS-IM v2.0
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988283
The ClinicalTrials.gov registry entry for NCT03988283 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Recurrent Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which Peripheral blood draw is the first listed.
NCT03988283 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03988283 about?
NCT03988283 is a clinical study titled "Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors". The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
What is the current status of trial NCT03988283?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-10-02. Estimated completion is 2031-02-28.
What conditions does trial NCT03988283 study?
This clinical trial studies the following conditions: Pediatric Recurrent Central Nervous System Tumors.
What interventions are being tested in trial NCT03988283?
The interventions under investigation include: Peripheral blood draw (PROCEDURE), Personalized neoantigen DNA vaccine (BIOLOGICAL), Papivax Biotech TDS-IM v2.0 (DEVICE).
Who is sponsoring clinical trial NCT03988283?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988283 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.